CL2017001514A1 - Inhibidores de erk - Google Patents
Inhibidores de erkInfo
- Publication number
- CL2017001514A1 CL2017001514A1 CL2017001514A CL2017001514A CL2017001514A1 CL 2017001514 A1 CL2017001514 A1 CL 2017001514A1 CL 2017001514 A CL2017001514 A CL 2017001514A CL 2017001514 A CL2017001514 A CL 2017001514A CL 2017001514 A1 CL2017001514 A1 CL 2017001514A1
- Authority
- CL
- Chile
- Prior art keywords
- erk inhibitors
- erk
- kinner
- pirrol
- ona
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS DE TIENO[2,3-C]PIRROL-4-ONA QUE INHIBEN LA ACTIVIDAD DE LA CINASA DE SEÑAL EXTRACELULAR REGULADA (ERK) Y PUEDEN SER ÚTILES EN EL TRATAMIENTOS DEL CÁNCER.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462095185P | 2014-12-22 | 2014-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001514A1 true CL2017001514A1 (es) | 2018-02-09 |
Family
ID=55135525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001514A CL2017001514A1 (es) | 2014-12-22 | 2017-06-13 | Inhibidores de erk |
Country Status (44)
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014331628B2 (en) | 2013-10-03 | 2018-08-30 | Kura Oncology, Inc. | Inhibitors of ERK and methods of use |
| WO2016106009A1 (en) | 2014-12-22 | 2016-06-30 | Eli Lilly And Company | Erk inhibitors |
| TWI704151B (zh) * | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| ES2989326T3 (es) | 2015-10-21 | 2024-11-26 | Otsuka Pharma Co Ltd | Compuestos de benzolactama como inhibidores de la proteína cinasa |
| JP2019523778A (ja) * | 2016-06-29 | 2019-08-29 | イーライ リリー アンド カンパニー | 膵癌の治療に使用するための、ｅｒｋ１／２阻害剤化合物と、ゲムシタビン、またはゲムシタビンおよびｎａｂ−パクリタキセルとの併用 |
| WO2018081204A1 (en) * | 2016-10-26 | 2018-05-03 | Li George Y | DEUTERATED N-(5-((4-ETHYLPIPERAZIN-1-YL)METHYL) PYRIDIN-2-YL)-5-FLUORO-4-(4-FLUORO-1-ISOPROPYL-2-METHYL-1H-BENZO[d]IMIDAZOL-6-YL)PYRIMIDIN-2-AMINE |
| GB201706327D0 (en) | 2017-04-20 | 2017-06-07 | Otsuka Pharma Co Ltd | A pharmaceutical compound |
| ES2926518T3 (es) | 2017-11-24 | 2022-10-26 | Janssen Pharmaceutica Nv | Compuestos de pirazolopiridinona |
| CN114366743A (zh) * | 2018-04-09 | 2022-04-19 | G1治疗公司 | 具有驱动致癌突变的癌症的治疗 |
| US12133841B2 (en) * | 2018-05-22 | 2024-11-05 | Js Innomed Holdings Ltd. | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof |
| CN113195000A (zh) | 2018-12-21 | 2021-07-30 | 第一三共株式会社 | 抗体-药物缀合物和激酶抑制剂的组合 |
| EP3946620B1 (en) * | 2019-03-27 | 2023-04-26 | Eli Lilly and Company | Salts of 5,6-dihydro-4h-thieno[2,3-c]pyrrol-4-one compound as erk inhibitors |
| WO2020192750A1 (zh) | 2019-03-28 | 2020-10-01 | 江苏恒瑞医药股份有限公司 | 噻吩并杂环类衍生物、其制备方法及其在医药上的应用 |
| CA3135070A1 (en) * | 2019-03-29 | 2020-10-08 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrroloheterocyclic derivative, preparation method therefor, and application thereof in medicine |
| WO2020231976A1 (en) * | 2019-05-16 | 2020-11-19 | Eli Lilly And Company | Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer |
| CN112457326B (zh) * | 2019-09-06 | 2022-02-15 | 上海凌达生物医药有限公司 | 一类芳香杂环并内酰胺类化合物、制备方法和用途 |
| CA3160899C (en) * | 2019-12-06 | 2024-04-16 | Medshine Discovery Inc. | Spiro compound serving as erk inhibitor, and application thereof |
| CN110950876B (zh) * | 2019-12-10 | 2021-08-17 | 上海凌达生物医药有限公司 | 一类呋喃并内酰胺类化合物、制备方法和用途 |
| WO2021216777A1 (en) * | 2020-04-21 | 2021-10-28 | The Trustees Of The Stevens Institute Of Technology | Erk inhibitors for cancer therapy |
| CN114315837B (zh) * | 2020-09-29 | 2023-06-16 | 江苏恒瑞医药股份有限公司 | 一种erk抑制剂的结晶形式及其制备方法 |
| CN116437915B (zh) * | 2020-09-29 | 2025-03-18 | 江苏恒瑞医药股份有限公司 | 一种吡咯并杂环类衍生物的晶型及其制备方法 |
| KR20240024963A (ko) * | 2021-06-28 | 2024-02-26 | 디3 바이오(우씨) 컴퍼니 리미티드 | 티아졸-락탐-스피로헤테로사이클릭 화합물 및 이의 적용 |
| EP4433059A1 (en) * | 2021-11-15 | 2024-09-25 | Erasca, Inc. | Thiophene ulk1/2 inhibitors and their use thereof |
| WO2023137297A2 (en) * | 2022-01-11 | 2023-07-20 | Suvalent Therapeutics, Inc. | 5,6-dihydro-4h-thieno[2,3-c]pyrrole sumo inhibitors and uses thereof |
| US20240352029A1 (en) * | 2023-04-14 | 2024-10-24 | Prelude Therapeutics Incorporated | CDK Inhibitors And Their Use As Pharmaceuticals |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4023048A1 (de) * | 1990-07-20 | 1992-01-23 | Basf Ag | Dicarbonsaeureimide, verfahren zu ihrer herstellung und ihre verwendung als herbizide |
| US7473691B2 (en) * | 2000-09-15 | 2009-01-06 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| JP4105949B2 (ja) * | 2000-09-15 | 2008-06-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼインヒビターとして有用なピラゾール化合物 |
| EP1916001B1 (en) | 2002-03-04 | 2011-05-25 | Imclone LLC | Human antibodies specific to KDR and uses thereof |
| ATE371656T1 (de) * | 2002-11-04 | 2007-09-15 | Vertex Pharma | Heteroaryl-pyrimidinderivate als jak-inhibitoren |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| US7803806B2 (en) * | 2005-11-03 | 2010-09-28 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
| EP2326627A1 (en) | 2008-08-20 | 2011-06-01 | Schering Corporation | Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| CN102245600A (zh) * | 2008-10-08 | 2011-11-16 | 百时美施贵宝公司 | 吡咯烷酮黑色素浓集激素受体-1拮抗剂 |
| JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
| BR112013007499A2 (pt) * | 2010-09-01 | 2016-07-12 | Genentech Inc | piridazinonas - métodos de criação e usos |
| AR087107A1 (es) | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| JP6068515B2 (ja) | 2012-03-01 | 2017-01-25 | アレイ バイオファーマ、インコーポレイテッド | セリン／トレオニンキナーゼ阻害剤 |
| AR090151A1 (es) | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| KR20150060687A (ko) * | 2012-09-28 | 2015-06-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 이중 안지오포이에틴-2/Dll4 결합제 및 항-VEGF-R 제제를 포함하는 약제학적 조합물 |
| TWI704151B (zh) * | 2014-12-22 | 2020-09-11 | 美商美國禮來大藥廠 | Ｅｒｋ抑制劑 |
| WO2016106009A1 (en) * | 2014-12-22 | 2016-06-30 | Eli Lilly And Company | Erk inhibitors |
-
2015
- 2015-12-09 TW TW104141368A patent/TWI704151B/zh not_active IP Right Cessation
- 2015-12-10 JO JOP/2015/0310A patent/JO3596B1/ar active
- 2015-12-11 AR ARP150104045A patent/AR102977A1/es unknown
- 2015-12-16 LT LTEP15823869.1T patent/LT3237423T/lt unknown
- 2015-12-16 TN TN2017000233A patent/TN2017000233A1/en unknown
- 2015-12-16 DK DK15823869.1T patent/DK3237423T3/da active
- 2015-12-16 AU AU2015369983A patent/AU2015369983C1/en not_active Ceased
- 2015-12-16 RS RS20190906A patent/RS59015B1/sr unknown
- 2015-12-16 UA UAA201706046A patent/UA119686C2/uk unknown
- 2015-12-16 BR BR112017011130A patent/BR112017011130A2/pt active Search and Examination
- 2015-12-16 TR TR2019/09887T patent/TR201909887T4/tr unknown
- 2015-12-16 EA EA201791133A patent/EA031659B1/ru not_active IP Right Cessation
- 2015-12-16 PT PT15823869T patent/PT3237423T/pt unknown
- 2015-12-16 NZ NZ731531A patent/NZ731531A/en not_active IP Right Cessation
- 2015-12-16 WO PCT/US2015/065940 patent/WO2016106029A1/en active Application Filing
- 2015-12-16 JP JP2017533381A patent/JP6445701B2/ja active Active
- 2015-12-16 KR KR1020177016748A patent/KR101917972B1/ko not_active Expired - Fee Related
- 2015-12-16 PL PL15823869T patent/PL3237423T3/pl unknown
- 2015-12-16 CN CN201580070315.6A patent/CN107108648B/zh active Active
- 2015-12-16 ME MEP-2019-201A patent/ME03490B/me unknown
- 2015-12-16 MD MDE20170231 patent/MD3237423T2/ro not_active IP Right Cessation
- 2015-12-16 SI SI201530773T patent/SI3237423T1/sl unknown
- 2015-12-16 PE PE2017001109A patent/PE20171043A1/es unknown
- 2015-12-16 MX MX2017008242A patent/MX371206B/es active IP Right Grant
- 2015-12-16 ES ES15823869T patent/ES2738406T3/es active Active
- 2015-12-16 EP EP15823869.1A patent/EP3237423B1/en active Active
- 2015-12-16 CR CR20170182A patent/CR20170182A/es unknown
- 2015-12-16 CA CA2966559A patent/CA2966559C/en active Active
- 2015-12-16 SG SG11201704521SA patent/SG11201704521SA/en unknown
- 2015-12-16 MA MA41251A patent/MA41251B1/fr unknown
- 2015-12-16 MY MYPI2017702263A patent/MY178426A/en unknown
- 2015-12-16 HU HUE15823869A patent/HUE045933T2/hu unknown
- 2015-12-16 US US14/970,588 patent/US9469652B2/en not_active Ceased
-
2016
- 2016-09-08 US US15/259,381 patent/US9526733B1/en active Active
-
2017
- 2017-04-20 ZA ZA2017/02786A patent/ZA201702786B/en unknown
- 2017-05-01 IL IL252065A patent/IL252065B/en active IP Right Grant
- 2017-05-15 SV SV2017005443A patent/SV2017005443A/es unknown
- 2017-05-16 DO DO2017000122A patent/DOP2017000122A/es unknown
- 2017-05-25 CO CONC2017/0005217A patent/CO2017005217A2/es unknown
- 2017-06-13 CL CL2017001514A patent/CL2017001514A1/es unknown
- 2017-06-19 GT GT201700134A patent/GT201700134A/es unknown
- 2017-06-20 PH PH12017501155A patent/PH12017501155B1/en unknown
- 2017-06-22 EC ECIEPI201738500A patent/ECSP17038500A/es unknown
-
2019
- 2019-05-22 US US16/419,141 patent/USRE48635E1/en active Active
- 2019-07-15 HR HRP20191268 patent/HRP20191268T1/hr unknown
- 2019-07-23 CY CY20191100777T patent/CY1121831T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001514A1 (es) | Inhibidores de erk | |
| TWD187904S (zh) | 追蹤裝置 | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| AU362319S (en) | Pet treat | |
| TWD170352S (zh) | 項鍊 | |
| CY1119419T1 (el) | C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε) | |
| PH12017500836A1 (en) | Transdermal formulations | |
| FR3024945B1 (fr) | Article absorbant avec graphismes | |
| TR201901348T4 (tr) | Metap-2 inhibitörleri olarak pirolidinon türevleri. | |
| AU363883S (en) | Tracking device | |
| MY165760A (en) | Absorbent article | |
| MX2017008450A (es) | Composiciones inhibidoras de nitrificacion microencapsuladas. | |
| BR112018005863A2 (pt) | endófitos de brachiaria e métodos relacionados | |
| UY36107A (es) | Composición microencapsulada inhibidora de la nitrificación | |
| MX2016011413A (es) | Formulaciones que comprenden xiloglucano polimérico como portador para agentes agronómicamente beneficiosos. | |
| AU361576S (en) | Extension member | |
| RS54907B1 (sr) | Upotreba odiparsila u lečenju mukopolisaharidoze | |
| TH1601001598A (th) | การใช้ทางการเกษตรของแบคทีเรียชนิดใหม่ของจีนัส Streptomyces | |
| BR112017008659A2 (pt) | ?métodos e compostos de agonista de gip? | |
| AU362428S (en) | Absorbent article | |
| AU201614421S (en) | Punching ball | |
| UA100258U (en) | PROTECTIVE GLOVE HOUSEHOLD | |
| UA97245U (en) | Succinic acid application to strengthen the antihypoxic effect of thiotriazoline and quercetin | |
| TWD169258S (zh) | 蹦床 | |
| UA88010U (ru) | Устройство для ушивания кожи при формировании эстетического рубца |